Browse the evidence

SGLT2 inhibitors reduce major adverse cardiovascular events (MACE) by 11% and heart failure hospitalization by 23% in patients with type 2 diabetes and established cardiovascular disease.

If you have Type 2 Diabetes and heart disease or heart failure, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs not only help control blood sugar but have been proven to significantly reduce the risk of heart attacks, strokes, and hospitalizations for heart failure, regardless of your current blood sugar levels.

High-fat diet consumption triggers rapid hypothalamic inflammation (via TLR4/JNK/NF-κB pathways) that causes central insulin and leptin resistance, uncoupling energy balance and driving obesity.

Focus on reducing saturated fats (like palmitic acid) in your diet, as they directly trigger brain inflammation that blocks satiety hormones. This isn't just about calories; it's about protecting your brain's ability to regulate hunger and metabolism.

Saturated fatty acids (SFAs) like palmitate cross the blood-brain barrier and accumulate in the hypothalamus, directly causing insulin and leptin resistance via TLR4 and JNK activation.

Limit intake of saturated fats (found in fatty meats, butter, cheese) to prevent them from entering the brain and blocking weight-regulating hormones.

Hypothalamic inflammation disrupts the blood-brain barrier (BBB), allowing peripheral inflammatory signals and immune cells to enter the brain, further exacerbating metabolic deregulation.

Long-term high-fat diets damage the brain's protective barrier, letting inflammation in. Reducing saturated fats may help maintain this barrier.

Physical activity and sleep duration are highly polygenic traits with significant heritability driven by central nervous system pathways, rather than just metabolic or muscular factors.

Your natural tendency to be active or sedentary has a genetic component, particularly linked to brain function. This doesn't mean you are stuck; it means you might need to work harder or use different strategies to build activity habits than others. Focus on consistency rather than intensity if starting out.

Twelve-week treatment with the GLP-1 analogue liraglutide (1.8 mg/day) reduces hepatic de novo lipogenesis (DNL) and improves adipose tissue insulin sensitivity, thereby decreasing lipotoxicity in patients with biopsy-proven non-alcoholic steatohepatitis (NASH).

For patients with NASH, a 12-week course of liraglutide (titrated to 1.8 mg daily) has been shown to directly reduce the liver's production of new fat (DNL) and improve how fat tissue responds to insulin. This dual action reduces the toxic fat spill-over (lipotoxicity) that drives liver damage. While weight loss occurs, the study suggests direct metabolic benefits on the liver and fat tissue independent of weight change alone.

Supplementation with the trans10cis12 (t10c12) isomer of conjugated linoleic acid (CLA) causes significant insulin resistance and worsens lipid profiles in obese men with the metabolic syndrome.

If you are obese and have signs of metabolic syndrome (like high blood pressure or high triglycerides), avoid supplements containing the trans10cis12 isomer of conjugated linoleic acid (CLA). While marketed for weight loss, this specific isomer has been shown to worsen insulin resistance and lower 'good' HDL cholesterol, potentially increasing your risk for type 2 diabetes and heart disease. Standard CLA mixtures also failed to improve body composition in this group.

In healthy elderly individuals, age-associated deterioration in glucose tolerance is driven by decreased insulin secretion and action, where the severity of insulin resistance is determined by body fatness rather than chronological age itself.

For older adults, maintaining low visceral fat and high aerobic fitness is more critical for glucose tolerance than chronological age. While beta-cell function declines with age, managing body composition can mitigate insulin resistance. Focus on preserving muscle mass and reducing visceral adiposity rather than accepting metabolic decline as inevitable.

Pioglitazone, GLP-1 receptor agonists (GLP-1RAs), and SGLT-2 inhibitors are pharmacological agents with potential utility in managing NASH, though GLP-1RAs show more consistent evidence for histological improvement.

If lifestyle changes are insufficient, discuss GLP-1 receptor agonists (like liraglutide or semaglutide) with your doctor. These drugs not only help control blood sugar but have shown the ability to resolve NASH in biopsy-proven cases. They are generally well-tolerated when titrated slowly.

DPP4 inhibitors (gliptins) treat type 2 diabetes by blocking the enzymatic degradation of incretin hormones (GLP-1 and GIP), thereby prolonging their half-life and enhancing glucose-dependent insulin secretion.

DPP4 inhibitors (gliptins) are oral medications for type 2 diabetes that work by keeping your body's natural insulin-boosting hormones active longer. They are generally well-tolerated, do not typically cause weight gain, and carry a low risk of dangerously low blood sugar compared to other treatments.

Inducible overexpression of VEGF-A in white adipose tissue (WAT) during early high-fat diet exposure promotes angiogenesis, induces a 'browning' phenotype (increased UCP1/PGC1α), and improves systemic metabolic health by enhancing insulin sensitivity and energy expenditure.

This research suggests that maintaining healthy blood vessel density in fat tissue is crucial for metabolic health. While this is a mouse study using genetic modification, it implies that factors supporting healthy vascularization (like exercise) may help prevent the hypoxia and inflammation associated with obesity.

FGF15/19 acts as an endocrine hormone to repress hepatic gluconeogenesis and stimulate glycogen synthesis, functioning as a post-prandial signal that complements insulin.

This paper describes FGF15/19 as a natural hormone released after eating that helps store energy as glycogen and stops the liver from making new glucose. It works alongside insulin but has its own unique pathway. For practical purposes, this highlights the importance of the post-meal state in metabolic health, though no specific intervention is prescribed.

FGF21 is induced by fasting and acts as a glucagon-like hormone to promote ketogenesis, gluconeogenesis, and fatty acid oxidation during starvation.

FGF21 is a hormone that rises when you fast, helping your body burn fat and make ketones for energy. It is a natural part of the starvation response, ensuring you don't run out of glucose.

Pharmacological administration of FGF21 improves insulin sensitivity, reduces hepatic triglycerides, and causes weight loss in obese rodents and primates.

Injecting FGF21 in obese animals improves insulin sensitivity, lowers liver fat, and reduces weight by increasing energy expenditure, even without eating less. This suggests a potential therapeutic avenue for metabolic disease.

Activation of brown adipose tissue (BAT) via beta-3 adrenergic receptor stimulation reduces plasma cholesterol and protects against atherosclerosis, but only in individuals with a functional hepatic apoE-LDL receptor clearance pathway.

Activating brown fat through cold exposure or specific medications can lower cholesterol and protect heart health, but only if your liver is healthy enough to clear the resulting cholesterol particles. If you have genetic conditions affecting your LDL receptors, this mechanism may not work for you.

In Type 2 Diabetes, elevated circulating levels of microRNA-144 (miR-144) directly inhibit the expression of Insulin Receptor Substrate 1 (IRS1), thereby impairing insulin signaling and contributing to insulin resistance.

This research identifies a specific molecular mechanism in Type 2 Diabetes where high levels of miR-144 block insulin signaling by reducing IRS1. For patients, this highlights that insulin resistance is driven by specific genetic regulatory failures, not just lifestyle factors. While this paper does not offer a direct treatment, it identifies miR-144 as a potential biomarker for disease severity and a target for future therapies aimed at restoring insulin sensitivity.

Chronic caloric surplus triggers a low-grade, chronic inflammatory state termed 'metaflammation' in metabolic tissues, which directly inhibits insulin signaling and promotes insulin resistance.

If you consistently eat more energy than you burn, your body doesn't just store fat; it starts sending inflammatory signals that block insulin. This 'metaflammation' makes it harder for your body to manage blood sugar and store energy efficiently. Reducing caloric surplus is the primary way to reduce this inflammatory burden and restore metabolic sensitivity.

Endoplasmic Reticulum (ER) stress, triggered by nutrient excess, activates the Unfolded Protein Response (UPR), which intersects with inflammatory pathways (via IRE-1, PERK, and ATF6) to inhibit insulin signaling and promote metabolic dysfunction.

Excess nutrients can overwhelm the cell's ability to process proteins, causing 'ER stress.' This stress activates specific cellular pathways (UPR) that interfere with insulin signaling. Managing caloric intake and reducing metabolic load can help alleviate this cellular stress.

Adiponectin inhibits spontaneous and catecholamine-induced lipolysis in non-obese humans via AMPK-dependent mechanisms, and its levels are decreased in obesity.

Adiponectin, an adipokine, helps inhibit fat breakdown in non-obese individuals. In obesity, adiponectin levels drop, potentially contributing to altered lipid metabolism. Maintaining healthy adiponectin levels through weight management and exercise is beneficial for metabolic health.

Rapid postnatal catch-up growth in children born with low birth weight or intrauterine growth restriction significantly increases the risk of adult obesity, insulin resistance, and metabolic syndrome.

For parents of small babies, aim for steady, healthy growth rather than rapid weight gain. Monitor growth charts and consult pediatricians to ensure catch-up growth is gradual, as rapid acceleration in infancy is linked to higher risks of obesity and insulin resistance later in life.

Maternal obesity and high pre-pregnancy BMI increase the risk of offspring being overweight, having higher body fat, and exhibiting insulin resistance in childhood, independent of birth weight.

Maintaining a healthy weight before pregnancy is one of the most effective ways to protect your child's long-term metabolic health. If you are overweight, focus on gradual, sustainable lifestyle changes before conception to reduce the risk of your child developing obesity and insulin resistance.

DNA methylation levels in specific genes (e.g., PGC-1α, FTO, TCF7L2) are altered in patients with Type 2 Diabetes and obesity, serving as potential biomarkers for diagnosis and treatment response.

Blood tests measuring DNA methylation patterns (epigenetic biomarkers) may soon help predict who is at risk for diabetes or who will respond to specific drugs like metformin, allowing for more personalized prevention and treatment strategies.

Maintaining high levels of PGC-1α during catabolic conditions (such as denervation or fasting) prevents muscle loss by inhibiting the transcriptional activity of FoxO3 and NF-κB, thereby blocking protein degradation pathways without affecting protein synthesis.

For those at risk of muscle wasting (e.g., due to illness or inactivity), keeping PGC-1α levels high is protective. This is best achieved through regular exercise, which naturally upregulates PGC-1α. This helps block the signals (FoxO3/NF-κB) that tell your muscles to break down, preserving mass even when you are not eating enough or are stressed.

GLP-1 receptor agonists (GLP-1RAs) provide superior glycemic control compared to DPP-4 inhibitors in type 2 diabetes, primarily due to higher pharmacological concentrations of GLP-1 and distinct tissue distribution patterns.

If oral diabetes medications are not controlling your blood sugar well enough, switching to a GLP-1 injection (like liraglutide or semaglutide) is likely to lower your A1c more effectively than switching to a DPP-4 inhibitor pill (like sitagliptin). GLP-1 injections also tend to promote weight loss, whereas DPP-4 inhibitors are generally weight-neutral. The trade-off is that GLP-1s require injections and may cause initial nausea.